Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Chelsea Therapeutics International Ltd. Stories

2013-04-08 08:25:54

LONDON, April 8, 2013 /PRNewswire/ -- The U.S. Supreme Court, last year, upheld President Obama's Affordable Care Act (ACA). The ACA is expected to have a significant impact on the biotechnology industry. While the healthcare reform is likely to result in significant increase in costs for the biotechnology industry in the near-term, the increase in the number of insured individuals is likely to benefit the industry in the long-term. For biotechnology companies such as BioMarin...

2012-05-29 14:21:16

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO) The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea's Northera (droxidopa) product, an...

2012-05-21 10:23:22

NEW YORK, May 21, 2012 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of North Carolina on behalf of investors who purchased Chelsea Therapeutics International Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP) stock between November 3, 2008 and March 28, 2012. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) For more information, click here: http://zlk.9nl.com/CHTP....

2012-04-20 14:21:01

NEW YORK, April 20, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea's Northera (droxidopa) product, an...

2012-04-05 14:21:03

NEW YORK, April 5, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea's Northera (droxidopa) product, an...

2012-02-27 07:55:00

VANCOUVER, British Columbia, Feb. 27, 2012 /PRNewswire-Asia/ -- Pennystocksinsiders.com (PSI) has issued insider trading reports and Equity Research for the following companies: Chelsea Therapeutics (NASDAQ:CHTP), Clearwire (NASDAQ:CLWR), EXCO Resources (NYSE:XCO), Kodiak Oil & Gas (NYSE:KOG), and Pacific Ethanol (NASDAQ:PEIX). (Logo: http://photos.prnewswire.com/prnh/20111214/HK22486LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to...

2008-11-13 09:00:37

CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical program for CH-4051, the second drug candidate from its portfolio of orally available, non-metabolized antifolates engineered to provide potent anti-inflammatory activity without the liver and kidney toxicities or tolerability related side effects associated with chronic methotrexate (MTX)...

2008-11-12 09:00:46

CHARLOTTE, N.C., Nov. 12, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will be hosting its 2008 analyst and institutional investor day from 9:30 AM to 12:00 PM on Friday, November 21, 2008 at The Grand Hyatt Hotel in New York City. The event will be moderated by Dr. Simon Pedder, President and CEO of Chelsea Therapeutics and will include an in-depth discussion of the Company's product pipeline, growth opportunities and development strategy including...

2008-11-03 09:00:40

* Responders Demonstrated Mean Reduction in Symptomatic Score of 4.6 Units and Increase of 27mmHg in Standing Systolic Blood Pressure CHARLOTTE, N.C., Nov. 3, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that data from the open-label titration portion of Chelsea's Phase III trial demonstrated patients treated with Droxidopa, a synthetic precursor to norepinephrine, showed a robust reduction in the severity of symptoms associated with...

2008-10-28 09:00:07

CHARLOTTE, N.C., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a novel metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. "Having recently received a favorable recommendation from an independent data safety monitoring board and now having completed...